Immunosuppressive Agents

• 

  Subject Areas on Research

  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. 
  • 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. 
  • 4D MRI of polycystic kidneys from rapamycin-treated Glis3-deficient mice. 
  • A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus. 
  • A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease. 
  • A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. 
  • A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. 
  • A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. 
  • A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. 
  • A model of sequential heart and composite tissue allotransplant in rats. 
  • A modern Cosmas and Damian: Sir Roy Calne and Thomas Starzl receive the 2012 Lasker~Debakey Clinical Medical Research Award. 
  • A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. 
  • A non-canonical RNA degradation pathway suppresses RNAi-dependent epimutations in the human fungal pathogen Mucor circinelloides. 
  • A novel approach to the treatment of chronic allograft nephropathy. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. 
  • A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. 
  • A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. 
  • A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. 
  • A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. 
  • A reactive metabolite as an immune suppressant. 
  • A role for leukotrienes in cyclosporine nephrotoxicity. 
  • A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. 
  • A systematic review of morphea treatments and therapeutic algorithm. 
  • A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. 
  • Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. 
  • Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. 
  • Acute graft-vs-host disease: pathobiology and management. 
  • Acute rejection and humoral sensitization in lung transplant recipients. 
  • Adenovirus infections in pediatric small bowel transplant recipients. 
  • Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Advances in myasthenia gravis. 
  • Advances in pancreas transplantation: the University of Wisconsin experience. 
  • Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 
  • After 62 years of regulating immunity, dexamethasone meets COVID-19. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. 
  • Alemtuzumab. 
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. 
  • Altered immune responses in apolipoprotein E-deficient mice. 
  • Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. 
  • An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. 
  • An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. 
  • An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. 
  • An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. 
  • An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. 
  • Annual literature review for clinical transplants 2005. 
  • Anti-Müllerian hormone: a better marker of ovarian damage from cyclophosphamide. 
  • Anti-thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival. 
  • Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work? 
  • Antibody desensitization therapy in highly sensitized lung transplant candidates. 
  • Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. 
  • Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. 
  • Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. 
  • Antioxidant nutrients protect against cyclosporine A nephrotoxicity. 
  • Antirheumatic medications in pregnancy and breastfeeding. 
  • Apoptotic Donor Cells in Transplantation. 
  • Aquaporin 4 blockade improves survival of murine heart allografts subjected to prolonged cold ischemia. 
  • Are autoantibodies the targets of B-cell-directed therapy? 
  • Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. 
  • Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). 
  • Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. 
  • Association of tacrolimus time-to-therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population. 
  • Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. 
  • Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. 
  • Asymmetric anterior uveitis as a delayed complication of treatment with systemic high-dose cytosine-arabinoside: a case report and literature review. 
  • Autoimmune lymphoproliferative syndrome: an update and review of the literature. 
  • Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. 
  • Autophagy modulates articular cartilage vesicle formation in primary articular chondrocytes. 
  • Avascular necrosis following bone marrow transplantation: a case-control study. 
  • B cell loss leading to remission in severe systemic lupus erythematosus. 
  • B cells and transplantation tolerance. 
  • B cells as a therapeutic target in autoimmune diseases. 
  • B cells in chronic graft-versus-host disease. 
  • BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. 
  • Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. 
  • Barriers to Taking Medications for Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers, and Clinic Staff. 
  • Basiliximab decreases the incidence of acute rejection after intestinal transplantation. 
  • Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. 
  • Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. 
  • Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. 
  • Belatacept: is there BENEFIT for liver transplantation too? 
  • Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. 
  • Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort. 
  • Bilateral episcleritis as a manifestation of cutaneous leukocytoclastic vasculitis. 
  • Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation. 
  • Biologics in organ transplantation. 
  • Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. 
  • Brequinar sodium potentiates the effects of cyclosporine in experimental small bowel transplantation. 
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. 
  • CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cynomolgus monkeys despite homeostatic T-cell activation. 
  • CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. 
  • CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. 
  • CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. 
  • CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. 
  • CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. 
  • CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection. 
  • CTLA-4-Mediated inhibition of early events of T cell proliferation. 
  • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. 
  • CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. 
  • Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. 
  • Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 
  • Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. 
  • Calcineurin mutants render T lymphocytes resistant to cyclosporin A. 
  • Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete Mucor circinelloides. 
  • Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. 
  • Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. 
  • Campath-1H in intestinal and multivisceral transplantation: preliminary data. 
  • Campath-1H in renal transplantation: The University of Wisconsin experience. 
  • Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. 
  • Campath-1H use in pediatric renal transplantation. 
  • Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. 
  • Cardiac allograft vasculopathy: A review. 
  • Cardiac transplantation in a pediatric patient with systemic sclerosis. 
  • Cavitary lung nodules as an extraintestinal manifestation of ulcerative colitis. 
  • Cellular and molecular targeting for nanotherapeutics in transplantation tolerance. 
  • Cellular targeting in autoimmunity. 
  • Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. 
  • Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. 
  • Chemotherapy-induced eccrine squamous syringometaplasia in an infant. 
  • Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. 
  • Chronic Graft-versus-Host Disease: A Long Road Ahead. 
  • Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. 
  • Clinical Outcomes of Older Kidney Transplant Recipients. 
  • Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. 
  • Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. 
  • Clinical aspects of MuSK antibody positive seronegative MG. 
  • Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. 
  • Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. 
  • Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study. 
  • Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Clinical pancreas preservation and transplantation. 
  • Clinical problem-solving. Index of suspicion. 
  • Clinical significance of eosinophils in suspicious or borderline renal allograft biopsies. 
  • Clinical tolerance 2008. 
  • Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. 
  • Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function. 
  • Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission. 
  • Colonic Crohn Disease After Cardiac Transplantation: Case Report and Literature Review. 
  • Colonic Diverticulitis in a 19-Year-Old Boy With Juvenile Idiopathic Arthritis: Surgical Implications of Chronic Immunosuppression. 
  • Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. 
  • Comparative effectiveness clinical trials to advance treatment of myasthenia gravis. 
  • Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. 
  • Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. 
  • Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. 
  • Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: An executive summary. 
  • Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. 
  • Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. 
  • Conversion from mycophenolate mofetil to azathioprine in renal allograft [corrected] patients within the first month posttransplantation. 
  • Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. 
  • Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. 
  • Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Correlations of test skin grafts and renal allograft function in human subjects genotyped for HL-A. 
  • Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation. 
  • Costimulation Blockade Resistant Rejection. 
  • Costimulation blockade: towards clinical application. 
  • Critical care aspects of lung transplantation. 
  • Critical care perspective on immunotherapy in lung transplantation. 
  • Crossing the bridge: large animal models in translational transplantation research. 
  • Crosstalk Between T and B Cells in the Germinal Center After Transplantation. 
  • Cryptococcosis in solid organ transplant recipients: current state of the science. 
  • Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. 
  • Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. 
  • Current and future preparative regimens for bone marrow transplantation in thalassemia. 
  • Current therapies for lupus nephritis in an ethnically heterogeneous cohort. 
  • Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. 
  • Cutaneous acquired toxoplasmosis in a child: a case report and review of the literature. 
  • Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. 
  • Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. 
  • Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. 
  • Cyclophosphamide for lupus during pregnancy. 
  • Cyclophosphamide in scleroderma lung disease. 
  • Cyclosporin A inhibits inositol 1,4,5-trisphosphate binding to its receptors and release of calcium from intracellular stores in peritoneal macrophages. 
  • Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. 
  • Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. 
  • Cytokine kinetics profiling in pediatric renal transplant recipients. 
  • Cytomegalovirus keratitis after penetrating keratoplasty. 
  • Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). 
  • De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years. 
  • De novo belatacept in clinical vascularized composite allotransplantation. 
  • Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. 
  • Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment. 
  • Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. 
  • Delayed cardiac xenograft rejection in a pig-to-baboon model treated with a tolerance-inducing regimen and donor bone marrow infusion. 
  • Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. 
  • Depression, Immunosuppressant Levels, and Clinical Outcomes in Postlung Transplant Recipients. 
  • Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant. 
  • Determination of the functional status of alloreactive T cells by interferon-gamma kinetics. 
  • Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. 
  • Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. 
  • Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes. 
  • Diagnostic and therapeutic challenges. 
  • Diarrhea in a Patient With Combined Kidney-Pancreas Transplant. 
  • Differential effects of donor-specific alloantibody. 
  • Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. 
  • Differential regulation of calcineurin isoforms in transplant patients: a new look at an old problem. 
  • Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. 
  • Dimethylfumarate effectively inhibits lymphangiogenesis via p21 induction and G1 cell cycle arrest. 
  • Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. 
  • Distinct granuloma responses in C57BL/6J and BALB/cByJ mice in response to pristane. 
  • Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. 
  • Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? 
  • Down-regulation of the orphan nuclear receptor ROR gamma t is essential for T lymphocyte maturation. 
  • Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. 
  • Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy. 
  • Economic impact of drug-eluting stents on hospital systems: a disease-state model. 
  • Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. 
  • Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. 
  • Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. 
  • Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. 
  • Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. 
  • Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. 
  • Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 
  • Effect of surrogate tolerogenesis on the vascular rejection of pig heart xenografts. 
  • Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. 
  • Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. 
  • Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk. 
  • Effects of Immunosuppressive Medications on Mitochondrial Function. 
  • Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. 
  • Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. 
  • Effects of immunosuppression and pretransplant splenectomy in newborn cardiac xenograft survival. 
  • Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 
  • Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management. 
  • Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and safety of mammalian target of rapamycin inhibitors following intestinal and multivisceral transplantation. 
  • Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 
  • Efficacy of remission-induction regimens for ANCA-associated vasculitis. 
  • Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. 
  • Endemic Fungal Infection Recommendations for Solid-Organ Transplant Recipients and Donors. 
  • Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. 
  • Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. 
  • Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. 
  • Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 
  • Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 
  • Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Evaluation and management of fungal infections in immunocompromised patients. 
  • Evaluation of Weight-Based Dose During Transition From Immediate-Release to Extended-Release Tacrolimus in Kidney Transplant Recipients. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • Evaluation of a delivery system providing long-term release of cyclosporine. 
  • Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events. 
  • Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. 
  • Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. 
  • Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 
  • Evidence-based management of bullous pemphigoid. 
  • Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings. 
  • Experience with 500 simultaneous pancreas-kidney transplants. 
  • Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. 
  • Experimental modeling of desensitization: What have we learned about preventing AMR? 
  • Expression of heme oxygenase-1 can determine cardiac xenograft survival. 
  • Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. 
  • Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response. 
  • FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression. 
  • FK 506 induction and rescue therapy in pancreas transplant recipients. 
  • FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes. 
  • FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 
  • FKBP12-Dependent Inhibition of Calcineurin Mediates Immunosuppressive Antifungal Drug Action in Malassezia. 
  • FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. 
  • FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. 
  • Factors affecting outcome in myasthenia gravis. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. 
  • Finding the right job for the tool: alemtuzumab and its role in renal transplantation. 
  • Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. 
  • Foot problems in the diabetic transplant recipient. 
  • Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. 
  • Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. 
  • Functional Characteristics and Phenotypic Plasticity of CD57+PD1- CD4 T Cells and Their Relationship with Transplant Immunosuppression. 
  • Fungal infections in transplant and oncology patients. 
  • Gaining insights into chronic natural killer cell leukemias through extensive characterization of an individual case. 
  • Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. 
  • Genetic regulation of pristane-induced oil granuloma responses. 
  • Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. 
  • Glutathione peroxidase-deficient smooth muscle cells cause paracrine activation of normal smooth muscle cells via cyclophilin A. 
  • Good fungi gone bad: the corruption of calcineurin. 
  • Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. 
  • Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids. 
  • Graft-versus-host disease prevention by rapamycin: cellular mechanisms. 
  • Graft-versus-host disease: the viewpoint from the donor T cell. 
  • Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. 
  • Guidance for liver transplant immunosuppression. 
  • Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. 
  • Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. 
  • Guidelines for immunizations in patients with inflammatory bowel disease. 
  • Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. 
  • HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. 
  • Haemopoietic stem-cell transplantation for systemic sclerosis. 
  • Hand transplantation in the United States: experience with 3 patients. 
  • Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. 
  • Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions. 
  • Heart transplantation in neonates and in children. 
  • Heart xenograft survival with chimeric pig donors and modest immune suppression. 
  • Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. 
  • Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. 
  • Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. 
  • Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. 
  • Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. 
  • Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. 
  • High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. 
  • High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. 
  • High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. 
  • High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. 
  • How I treat refractory chronic graft-versus-host disease. 
  • How I treat thrombocytopenia in pregnancy. 
  • How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? 
  • Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. 
  • Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein. 
  • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. 
  • Hyperbaric oxygen and cyclosporine as a combined treatment regimen to prevent skin allograft rejection in immunohistoincompatible mice. 
  • Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. 
  • Hyperlipidemia and transplantation: etiologic factors and therapy. 
  • IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. 
  • IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses. 
  • IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection. 
  • Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. 
  • Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. 
  • Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. 
  • Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. 
  • Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. 
  • Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. 
  • IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients. 
  • Ileocolonic perforation. A complication following renal transplantation. 
  • Imaging findings of hemorrhagic cystitis in pediatric oncology patients. 
  • Immune reconstitution syndrome in a patient with disseminated histoplasmosis and steroid taper: maintaining the perfect balance. 
  • Immune regulation by glucocorticoids. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab. 
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. 
  • Immunologic considerations in composite tissue transplantation: overview. 
  • Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD. 
  • Immunomodulation of human CD8⁺ T cells by thymoglobulin in vitro. 
  • Immunoregulation and tolerance. 
  • Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 
  • Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus. 
  • Immunosuppression in Autoimmune Hepatitis: Is There an End Game? 
  • Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading? 
  • Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world. 
  • Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. 
  • Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. 
  • Immunosuppressive effects of subglutinol derivatives. 
  • Immunosuppressive protocols and immunological challenges related to hand transplantation. 
  • Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. 
  • Immunosuppressive therapies in myasthenia gravis. 
  • Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease. 
  • Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. 
  • Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 
  • Impact of Immunosuppressive Agents on Clinical Manifestations and Outcome of Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Analysis in 2 Large, Prospectively Evaluated Cohorts. 
  • Impact of Tacrolimus Trough Variability on Acute Rejection Following Lung Transplantation. 
  • Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. 
  • Impact of pronase on flow cytometric crossmatch outcome. 
  • Impact of psychosocial factors on medication level variability index and outcomes in pediatric liver transplant recipients. 
  • Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia. 
  • Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. 
  • Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis. 
  • In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. 
  • Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary? 
  • Incidence, timing, and histologic grade of acute rejection in small bowel transplant recipients. 
  • Incisional Infections after Renal Transplant: Outcome Data From 238 Consecutive Recipients. 
  • Increased expression of estrogen receptor beta in pachytene spermatocytes after short-term methoxyacetic acid administration. 
  • Increased kidney transplantation utilizing expanded criteria deceased organ donors with results comparable to standard criteria donor transplant. 
  • Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire? 
  • Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Induction immunosuppression in liver transplantation: a review. 
  • Induction immunosuppression. 
  • Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. 
  • Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. 
  • Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. 
  • Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. 
  • Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. 
  • Inflammatory bowel disease following solid organ transplantation. 
  • Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant. 
  • Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. 
  • Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. 
  • Initial experience using rapamycin immunosuppression in pediatric intestinal transplant recipients. 
  • Interleukin-15 receptor blockade in non-human primate kidney transplantation. 
  • International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. 
  • International consensus guidance for management of myasthenia gravis: Executive summary. 
  • Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. 
  • Intestinal Perforation in Renal Transplant Recipients: A Single Center Experience of 2123 Recipients. 
  • Intestinal and hepatic complications of human bone marrow transplantation. Part I. 
  • Intestinal transplantation. 
  • Intestinal transplantation: the University of Wisconsin experience. 
  • Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. 
  • Is tolerance induction the answer to adolescent non-adherence? 
  • Islands of Inflammation: Neurosarcoidosis. 
  • J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. 
  • Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. 
  • Juvenile dermatomyositis: recognition and treatment. 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up. 
  • Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy. 
  • Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. 
  • LMP-420, a small molecular inhibitor of TNF-α, prolongs islet allograft survival by induction of suppressor of cytokine signaling-1: synergistic effect with cyclosporin-A. 
  • Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. 
  • Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. 
  • Laryngeal transplantation in the setting of cancer: a rat model. 
  • Late graft loss and long-term outcome after isolated intestinal transplantation in children. 
  • Less Is More in Post Pediatric Heart Transplant Care. 
  • Life threatening liver disease during treatment with monoclonal antibodies. 
  • Liver transplantation at the University of Wisconsin. 
  • Liver transplantation for liver malignancies in Wilson's disease: two novel cases. 
  • Liver transplantation in an adolescent with acute liver failure from acute lymphoblastic leukemia. 
  • Liver transplantation. 
  • Living unrelated kidney donation: an underutilized resource? 
  • Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. 
  • Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. 
  • Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. 
  • Long-term management of the liver transplant patient: recommendations for the primary care doctor. 
  • Long-term outcomes and management of the heart transplant recipient. 
  • Long-term outcomes and quality of life after intestine transplantation. 
  • Long-term outcomes in simultaneous kidney-pancreas transplant recipients. 
  • Long-term tolerance of islet allografts in nonhuman primates induced by apoptotic donor leukocytes. 
  • Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. 
  • Lung Transplantation and the Era of the Sensitized Patient. 
  • Lung transplantation at Duke University Medical Center. 
  • Lung transplantation: advances in immunosuppression. 
  • Lupus activity in pregnancy. 
  • Lupus-related myelitis: serial MR findings. 
  • Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. 
  • Lymphodepletional strategies in transplantation. 
  • Machine learning predicts stem cell transplant response in severe scleroderma. 
  • Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. 
  • Management of biliary complications after heart transplantation. 
  • Management of childhood onset nephrotic syndrome. 
  • Management of patients with confirmed and presumed mucous membrane pemphigoid undergoing entropion repair. 
  • Management patterns of childhood-onset nephrotic syndrome. 
  • Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. 
  • Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model. 
  • Meeting Report of the 13th Congress of the International Society of Vascularized Composite Allotransplantation. 
  • Memory T-cell-specific therapeutics in organ transplantation. 
  • Methods to prevent rejection of homografts in man: a report on living related kidney donor selection by HL-A genotyping. 
  • Methotrexate treatment for sarcoid-associated panuveitis. 
  • Minimal manifestation status and prednisone withdrawal in the MGTX trial. 
  • Mitomycin C-augumented trabeculectomy with postoperative wound modulation in pediatric glaucoma. 
  • Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 
  • Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. 
  • Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. 
  • Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. 
  • Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. 
  • Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. 
  • Mycophenolate mofetil in myasthenia gravis: the unanswered question. 
  • Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. 
  • Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. 
  • Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. 
  • Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. 
  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. 
  • Myristoylation of calcineurin B is not required for function or interaction with immunophilin-immunosuppressant complexes in the yeast Saccharomyces cerevisiae. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • Nanoparticle Platforms for Antigen-Specific Immune Tolerance. 
  • Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. 
  • Natural product ligands of FKBP12: Immunosuppressive antifungal agents FK506, rapamycin, and beyond. 
  • Nerve activity-dependent modulation of calcineurin signaling in adult fast and slow skeletal muscle fibers. 
  • New and emerging disease modifying therapies for multiple sclerosis. 
  • New and emerging treatments for patients with uveitis. 
  • New therapeutics in rheumatoid arthritis. 
  • Next-generation drug-eluting stents: a spirited step forward or more of the same. 
  • Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. 
  • Non-human to human organ transplantation: its biologic basis and a potential role for radiation therapy. 
  • Nonadherence is associated with late rejection in pediatric heart transplant recipients. 
  • Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). 
  • Nonmelanoma skin cancer in inflammatory bowel disease: a review. 
  • North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. 
  • North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. 
  • Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 
  • Novel immunosuppressive agents in tolerance induction. 
  • Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • Of ends and means. 
  • Omalizumab use during pregnancy for CIU: a tertiary care experience. 
  • On the Discovery of TOR As the Target of Rapamycin. 
  • Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. 
  • Operational immune tolerance towards transplanted allogeneic pancreatic islets in mice and a non-human primate. 
  • Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial. 
  • Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. 
  • Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. 
  • Outcomes of primary total joint arthroplasty after lung transplantation. 
  • Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). 
  • Overcoming Chronic Rejection-Can it B? 
  • PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. 
  • Pancreas transplantation at the University of Wisconsin. 
  • Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. 
  • Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. 
  • Patient preferences for surgical versus medical therapy for ulcerative colitis. 
  • Patient-Reported Chronic Pain Outcomes After Lung Transplantation. 
  • Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Perforation of the gastrointestinal tract following renal transplantation. 
  • Peripheral blood detection of systemic graft-specific xeno-antibodies following transplantation of human neural progenitor cells into the porcine spinal cord. 
  • Persistent and Prolonged Parvovirus B19 Viremia in a Pediatric Patient With Acute Lymphoblastic Leukemia. 
  • Pharmaceutical expenses after kidney and kidney-pancreas transplantation. 
  • Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: results of Pediatric AIDS Clinical Trials Study 402. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. 
  • Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. 
  • Piceatannol in combination with low doses of cyclosporine A prolongs kidney allograft survival in a stringent rat transplantation model. 
  • Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. 
  • Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. 
  • Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. 
  • Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Polypoidal choroidal vasculopathy and systemic lupus erythematosus. 
  • Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates. 
  • Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. 
  • Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). 
  • Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. 
  • Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 
  • Postoperative management of heart transplantation patients. 
  • Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. 
  • Potential of costimulation-based therapies for composite tissue allotransplantation. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection. 
  • Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. 
  • Pregnancy and myasthenia gravis. 
  • Pregnancy in transplant recipients. 
  • Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. 
  • Preliminary experience with FK 506 in pancreas transplant recipients. 
  • Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. 
  • Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. 
  • Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. 
  • Prevention of autoimmune islet allograft destruction by engraftment of donor T cells. 
  • Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. 
  • Primary central nervous system posttransplant lymphoproliferative disorders. 
  • Progesterone-induced immunosuppression is not mediated through the progesterone receptor. 
  • Progesterone-induced immunosuppression. 
  • Prognosis of patients with suspected primary CNS angiitis and negative brain biopsy. 
  • Progression of idiopathic pulmonary fibrosis in native lungs after single lung transplantation. 
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. 
  • Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. 
  • Proline isomerases at the crossroads of protein folding, signal transduction, and immunosuppression. 
  • Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Protein serine/threonine phosphatases--new avenues for cell regulation. 
  • Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population. 
  • Pseudo-Pelger-Huët anomaly in a 58-year-old woman treated with mycophenolate mofetil for flare of systemic lupus erythematosus. 
  • Pulmonary drug toxicity: radiologic and pathologic manifestations. 
  • Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis. 
  • Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. 
  • Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. 
  • Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model. 
  • Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction. 
  • Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. 
  • Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. 
  • Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. 
  • Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. 
  • Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. 
  • Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. 
  • Rapamycin increases transforming growth factor-beta mRNA expression in immortalized rat proximal renal tubular cells. 
  • Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats. 
  • Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. 
  • Reasons for cesarean and medically indicated deliveries in pregnancies in women with systemic lupus erythematosus. 
  • Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. 
  • Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy. 
  • Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. 
  • Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus. 
  • Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. 
  • Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. 
  • Rejection of canine cardiac allografts. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Relationship between antithymocyte globulin, T cell phenotypes, and clinical outcomes in pediatric kidney transplantation. 
  • Renal endoplasmic reticulum stress is coupled to impaired autophagy in a mouse model of GSD Ia. 
  • Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. 
  • Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. 
  • Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial. 
  • Renal transplantation in children. 
  • Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. 
  • Reperfusion edema after lung transplantation: effect of daclizumab. 
  • Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. 
  • Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. 
  • Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). 
  • Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. 
  • Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. 
  • Retrospective analysis of the use of cyclosporine in myasthenia gravis. 
  • Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry. 
  • Reversal of acute allograft rejection using immunotoxin. 
  • Reversal of severe late left ventricular failure after pediatric heart transplantation and possible role of plasmapheresis. 
  • Rheumatologic manifestations of cancer. 
  • Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. 
  • Risk factors for BK polyomavirus nephritis in renal allograft recipients. 
  • Risk factors in necrotizing fasciitis: a case involving Cryptococcus neoformans. 
  • Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. 
  • Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. 
  • Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. 
  • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. 
  • Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
  • Role of endomyocardial biopsy in rejection surveillance after heart transplantation in neonates and children. 
  • Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. 
  • Role of low-dose calcineurin inhibitor regimens in pediatric kidney transplantation. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. 
  • Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study. 
  • Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. 
  • Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model. 
  • Selenium-binding protein-1 in smooth muscle cells is downregulated in a rhesus monkey model of chronic allograft nephropathy. 
  • Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. 
  • Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era. 
  • Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients. 
  • Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. 
  • Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. 
  • Signal-transduction cascades as targets for therapeutic intervention by natural products. 
  • Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. 
  • Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 
  • Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. 
  • Sirolimus monotherapy following Campath-1H induction. 
  • Solid-organ transplantation in older adults: current status and future research. 
  • Spectrum of immune-mediated inner ear disease and cochlear implant results. 
  • Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection. 
  • Starting well: induction immunosuppression after organ transplantation. 
  • Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. 
  • Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials. 
  • Steps toward transplantation tolerance in the clinic. 
  • Stereoselective synthesis and osteogenic activity of subglutinols A and B 
  • Steroid Regimen for Children with Nephrotic Syndrome Relapse. 
  • Steroid treatment for myasthenia gravis: steroids have an important role. 
  • Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. 
  • Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. 
  • Strategies for minimizing immunosuppression in kidney transplantation. 
  • Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus. 
  • Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. 
  • Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. 
  • Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. 
  • Subglutinol A, an immunosuppressive α-pyrone diterpenoid from Fusarium subglutinans, acts as an estrogen receptor antagonist. 
  • Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. 
  • Successful bone marrow transplantation of an adolescent young adult female with pregnancy-associated aplastic anemia. 
  • Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). 
  • Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 
  • Survival after bronchiolitis obliterans syndrome. 
  • Susac syndrome with transient inverted vision. 
  • Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. 
  • Symptomatic pulmonary allograft Kaposi's sarcoma in two lung transplant recipients. 
  • Synthesis and Biological Evaluation of Subglutinol Analogs for Immunomodulatory Agents. 
  • Synthetic peptide corresponding to a conserved domain of the retroviral protein p15E blocks IL-1-mediated signal transduction. 
  • System for integrated adherence monitoring: real-time non-adherence risk assessment in pediatric kidney transplantation. 
  • Systemic lupus erythematosus. 
  • Systemic lupus erythematosus. Diagnosis and treatment. 
  • T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. 
  • TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 
  • Tacrolimus and sirolimus: when bad things happen to good drugs. 
  • Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. 
  • Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. 
  • Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. 
  • Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. 
  • Tailored use of belatacept in adolescent kidney transplantation. 
  • Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation. 
  • Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. 
  • Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. 
  • Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 
  • Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. 
  • Temporal Changes in the Impact of HLA Mismatching Among Pediatric Kidney Transplant Recipients. 
  • Th17 cell inhibition in a costimulation blockade-based regimen for vascularized composite allotransplantation using a nonhuman primate model. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • Thalidomide for recalcitrant nodular scleritis in sarcoidosis. 
  • Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. 
  • The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. 
  • The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. 
  • The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. 
  • The NF-kappa B inhibitor, tepoxalin, suppresses surface expression of the cell adhesion molecules CD62E, CD11b/CD18 and CD106. 
  • The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 
  • The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 
  • The RAM1 gene encoding a protein-farnesyltransferase beta-subunit homologue is essential in Cryptococcus neoformans. 
  • The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma. 
  • The TOR kinases link nutrient sensing to cell growth. 
  • The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. 
  • The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 
  • The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. 
  • The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. 
  • The case for treatment of monogenic SRNS with calcineurin inhibitors. 
  • The clinical application of monoclonal antibody therapies in renal transplantation. 
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. 
  • The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. 
  • The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P: an understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell. 
  • The effect of 15-deoxyspergualin on hamster-to-rat cardiac xenograft survival. 
  • The effects of cytotoxic therapy in progressive IgA nephropathy. 
  • The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care. 
  • The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. 
  • The expression of plasma nucleosomes in mice undergoing in vivo apoptosis. 
  • The heart is just a muscle. 
  • The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 
  • The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. 
  • The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. 
  • The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients. 
  • The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. 
  • The impact of the host on fungal infections. 
  • The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. 
  • The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis. 
  • The incidence and management of pulmonary mycosis in renal allograft patients. 
  • The influence of RS-61443 on antibody-mediated rejection. 
  • The management of chronic graft-versus-host disease. 
  • The management of myasthenia gravis in pregnancy. 
  • The management of pediatric systemic lupus erythematosus. 
  • The natural history of renal function following orthotopic heart transplant. 
  • The past, present, and future of costimulation blockade in organ transplantation. 
  • The potential of xenotransplants. 
  • The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends. 
  • The spectrum of ciclosporin nephrotoxicity. 
  • The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. 
  • The treatment of patients with myasthenia gravis. 
  • Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project. 
  • Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients. 
  • Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine. 
  • Therapy for granulomatous angiitis. 
  • Therapy of rheumatoid arthritis: new developments and trends. 
  • Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. 
  • Thoracic organ transplantation at Papworth Hospital. 
  • Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. 
  • Timing and Number of Cutaneous Squamous Cell Carcinomas in Transplant Recipients. 
  • Tolerance and the "Holy Grail" of transplantation. 
  • Total respiratory support from swine lungs in primate recipients. 
  • Total synthesis, assignment of the absolute stereochemistry, and structure-activity relationship studies of subglutinols A and B. 
  • Transmission of latent cytomegalovirus in a murine kidney tissue transplantation model. 
  • Transplant Immunosuppression Management and COVID-19. 
  • Transplantation immunology: solid organ and bone marrow. 
  • Transplanted carcinoma in an immunosuppressed patient. 
  • Treatment Response in Sympathetic Ophthalmia as Assessed by Widefield OCT Angiography. 
  • Treatment of Eosinophilic Fasciitis With Sirolimus. 
  • Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure. 
  • Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. 
  • Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. 
  • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 
  • Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. 
  • Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis: etanercept, vascular function and endothelial progenitor cells in psoriasis. 
  • Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. 
  • Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States. 
  • Type of Organ Transplanted Impacts the Risk and Presentation of Cutaneous Squamous Cell Carcinoma in Transplant Recipients. 
  • Unique aspects of rejection and tolerance in liver transplantation. 
  • Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. 
  • Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. 
  • Use of Autologous Serum Tears for the Treatment of Ocular Surface Disease From Patients With Systemic Autoimmune Diseases. 
  • Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America. 
  • Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 
  • Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan's syndrome. 
  • Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. 
  • Utility of fiber-optic bronchoscopy in pulmonary infections among abdominal solid-organ transplant patients: A comprehensive review. 
  • Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. 
  • Vascularized composite allotransplants as a mechanistic model for allograft rejection - an experimental study. 
  • Vasculitis and Pregnancy. 
  • What should work, may not. 
  • What started this? Debilitating longitudinally-extensive myelitis. 
  • What's new in childhood organ transplantation. 
  • What's next in the pipeline. 
  • Wilms Tumor After Orthotopic Liver Transplant in a Patient With Alagille Syndrome. 
  • [A severe course of bullous pemphigoid in a young man]. 
  • [Effect of intrathecal pumping morphine on immunological function in rats with formalin pain]. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Guan, Ziqiang, Research Professor in Biochemistry, Biochemistry
  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • MacLeod, Amanda S, Adjunct Associate Professor in the Department of Dermatology, Integrative Immunobiology
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society